Kiwi Biosciences Analysis: $130K Raised
What is Kiwi Biosciences?
Kiwi Biosciences develops FODZYME®, an enzyme blend that aids digestion of high FODMAP foods, enabling comfortable meal enjoyment for individuals.
Employees
10
Founded
2020
Revenue
$1.2M
Business Model
Direct-to-consumer sales model with revenue from product sales and partnerships.
Product Features & Capabilities
- FODZYME® enzyme blend, home kit, on-the-go kit, anywhere bundle, aids in digestion of foods high in FODMAPs, allows enjoyment of meals without discomfort.
Pricing
- Home Kit: From $65.00
- On-the-Go Kit: From $65.00
- Anywhere Bundle: From $119.00
How much Kiwi Biosciences raised
1 - $0.13M
2020Lead Investor: Y Combinator, North South Ventures
Who are the founders of Kiwi Biosciences
AL
Anjie Liu
Founder
DH
David Hachuel Gurska
Founder
Competitors Overview
Kiwi Biosciences, which develops FODZYME®, faces competition from several companies in the digestive health market, particularly those focusing on FODMAP digestion. Key competitors include:
- Casa de Sante: This company offers Low FODMAP Certified Digestive Enzymes, specifically designed for i
Investors
- Acacia Venture Capital Partners
- Jude Gomila
- Emily Leproust
- (Additional investors not specified)
Market Focus
Kiwi Biosciences primarily focuses on the health and wellness industry, specifically in the area of digestive health through the development of enzyme products that aid in the digestion of FODMAP-rich foods.
See something that needs updating? Suggest edits to this profile.